Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com

Inclusion Criteria:

- Male and female, ages 18 to 70 years

- Diagnosis of plaque psoriasis for 6 months

- Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy
test, must not be pregnant, lactating, breastfeeding or planning pregnancy

- Males who are sexually active with WOCBP must agree to follow instructions for
method(s) of contraception for the duration of treatment plus 5 half-lives of the
study drug plus 90 days.

Exclusion Criteria:

- Any significant acute or chronic medical illness

- Blood transfusion within 4 weeks of study drug administration

- Inability to tolerate oral medication

- Positive hepatitis-B (HBV) surface antigen

- Positive hepatitis-C (HCV) antibody

- Any history or risk for tuberculosis (TB)

- Any major illness/condition or evidence of an unstable clinical condition

- Chest X-ray findings suspicious of infection at screening

- has received ustekinumab, secukinumab or ixekizumab within 6 months of first
administration of study medication

- Has received anti-Tumor Necrosis Factor (TNF) inhibitor(s) within 2 months of first
administration of study medication

- Has received Rituximab within 6 months of first administration of study medication

- Topical medications/treatments for psoriasis within 2 weeks of the first
administration of any study medication

- Any systemic medications/treatments for psoriasis within 4 weeks of the first
administration of any study medication

Other protocol defined inclusion/exclusion criteria could apply